ArticleAvicenna journal of medical biotechnology
Antidiabetic Activity of
Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07240246 (Effect of a Dietary Supplement), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of a Dietary Supplement (FitLine TopShape) on the Incretin Response
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study addresses the increasing prevalence of type 2 Diabetes Mellitus (T2DM) and the need for alternative, cost-effective medications. The research problem focuses on the need to further study the dose effectiveness of Methods: The methodology employed an experimental research design with 30 Wistar rats divided into six groups, each receiving different inductions and doses. Parameters were measured using Elisa, and histological analysis of pancreatic tissue was conducted using HE staining. Results: The Kruskal-Wallis test revealed significant differences in each group for the GLP-1 (p=0.003). However, the DPP4 test suggested a lack of significant difference in each group (p=0.192), and the GLUT5 test showed insignificant changes between each group (p=0.119). The ANOVA analysis on alpha-glucosidase revealed no statistically significant differences among the groups (p=0.202). Additionally, a qualitative examination of the histological analysis of pancreatic tissue indicated an improvement in the condition of the pancreatic tissue. Conclusion: MCE can increase GLP-1 levels, lower DPP-4, lower alpha-glucosidase, and raise GLUT5. However, there are no significant differences between other groups and the morphology of pancreatic tissue in rat model T2DM at a dose of 300
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.